Various imaging modalities show low sensitivity for detecting pelvic lymph node invasion prior to surgery in patients with intermediate risk prostate cancer.

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation ...

Commonwealth Health Wilkes-Barre General Hospital is the first institution in our area to offer the new FDA approved and NCCN-indicated, prostate specific membrane antigen (PSMA) imaging agent to ...

PSMA-PET imaging has higher sensitivity than conventional imaging and can detect radiorecurrent prostate cancer at lower PSA levels. PSMA-PET imaging can detect radiorecurrent prostate cancer lesions ...

Patient undergoing PET/CT Investigators zero in on which patients might benefit most from PSMA-PET-guided salvage radiation therapy for post-RP recurrent prostate cancer. Study findings presented at ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

Lantheus’ product, PYLARIFY (piflufolastat F18) injection, is the first and only commercially available and FDA-approved PSMA-targeted PET imaging agent for prostate cancer NORTH BILLERICA, Mass., ...

Rarely has a footnote garnered so much positive attention, but a reference in the newly updated prostate cancer guidelines from the National Comprehensive Cancer Network (NCCN) has prostate cancer ...

PSMA-PET scans detected metastatic disease in 46% of patients, indicating understaging by conventional imaging in high-risk nonmetastatic hormone-sensitive prostate cancer. The study involved 182 ...

The FDA has approved flotufolastat F 18 injection for positron emission tomography of prostate-specific membrane antigen–positive lesions in certain men with prostate cancer. The FDA has approved ...

Fluorine-18 prostate-specific membrane antigen (PSMA)-1007 PET/CT was superior to multiparametric MRI for primary locoregional staging of prostate cancer, according to results from a phase II ...

University of California prostate cancer experts will share clinical insights at the first annual PSMA Conference, “PSMA PET and RLT: Present and Future.” The conference will take place online and ...